Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed non-squamous/adenocarcinoma or adenosquamous NSCLC that is either unresectable Stage IIIb/c disease not amenable for definitive chemoradiation, or Stage IV. * Age ≥ 18 years * ECOG performance status 0 to 1. * Received at least 2 but no more than 4 prior lines of systemic therapy for advanced NSCLC * Disease progression during or following the most recent systemic anti-cancer therapy. * Positive FOLR1 expression per central testing * At least 1 measurable target lesion per RECIST 1.1 * Adequate organ function Exclusion Criteria: * Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulin inhibitor * Untreated central nervous system metastases * Ongoing immunosuppressive therapy, except for treated brain metastases, per criterion above. * History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to antibody-related fusion protein treatment * Pre-existing clinically significant ocular disorders, severe chronic obstructive pulmonary disease or asthma, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition * Previous solid organ transplantation * Concurrent participation in another therapeutic treatment trial